Arcus Biosciences, Inc. (RCUS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.17B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.00M; Retained Earnings (Accumulated Deficit)USD $-1.70B; Stockholders' Equity Attributable to ParentUSD $464.00M.
- 2026-03-31: Common Stock, Value, IssuedUSD $2.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.00M; Retained Earnings (Accumulated Deficit)USD $-1.61B; Stockholders' Equity Attributable to ParentUSD $524.00M.
- 2025-12-31: Common Stock, Value, IssuedUSD $2.12B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-1.49B; Stockholders' Equity Attributable to ParentUSD $631.00M.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.81B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-1.38B; Stockholders' Equity Attributable to ParentUSD $436.00M.
Arcus Biosciences, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.17B | $-1.00M | $-1.70B | $464.00M | 3 month · $15.00M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $2.14B | $-1.00M | $-1.61B | $524.00M | 3 month · $19.00M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $2.12B | $0.00 | $-1.49B | $631.00M | 12 month · $60.00M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.81B | (m) | $-1.38B | $436.00M | 3 month · $14.00M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.79B | (m) | $-1.24B | $549.00M | 3 month · $15.00M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.77B | (m) | $-1.24B | $531.00M | 3 month · $16.00M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.62B | (m) | $-1.13B | $485.00M | 12 month · $76.00M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.60B | $1.00M | $-1.04B | $565.00M | 3 month · $19.00M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.58B | $-1.00M | $-946.00M | $635.00M | 3 month · $20.00M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $1.56B | $-1.00M | $-853.00M | $707.00M | 3 month · $20.00M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.31B | $0.00 | $-849.00M | $462.00M | 12 month · $73.00M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.29B | $-3.00M | $-768.00M | $520.00M | 3 month · $18.00M | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | $1.27B | $-4.00M | $-697.00M | $566.00M | 3 month · $18.00M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.23B | $-4.00M | $-622.00M | $600.00M | 3 month · $19.00M | $0.00 | (m) | (m) | (m) |
| 2022-12-31 | $1.21B | $-7.00M | $-542.00M | $657.00M | 12 month · $65.00M | $0.00 | (m) | (m) | (m) |
| 2022-09-30 | $7.00K | $-9.80M | $-474.90M | $699.00M | 3 month · $16.00M | $0.00 | $1.18B | (m) | (m) |
| 2022-06-30 | $7.00K | $-7.24M | $-409.98M | $747.00M | 3 month · $15.00M | $0.00 | $1.16B | (m) | 6 month · $0.00 |
| 2022-03-31 | $7.00K | $-4.66M | $-343.35M | $797.00M | 3 month · $17.00M | $0.00 | $1.14B | (m) | 3 month · $0.00 |
| 2021-12-31 | $1.12B | $-1.00M | $-275.00M | $842.00M | 12 month · $55.00M | $0.00 | $1.12B | (m) | 12 month · $0.00 |
| 2021-09-30 | $7.00K | $-92.00K | $-554.72M | $542.61M | 3 month · $14.59M | $0.00 | $1.10B | (m) | 3 month · $0.00 9 month · $0.00 |
| 2021-06-30 | $7.00K | $-46.00K | $-476.75M | $604.55M | 3 month · $13.37M | $0.00 | $1.08B | (m) | 6 month · $0.00 |
| 2021-03-31 | $7.00K | $-2.00K | $-400.78M | $664.79M | 3 month · $12.76M | $0.00 | $1.07B | (m) | 3 month · $0.00 |
| 2020-12-31 | $6.00K | $44.00K | $-328.18M | $502.00M | 12 month · $22.00M | $0.00 | $830.44M | 12 month · $21.63M | 12 month · $0.00 |
| 2020-09-30 | $6.00K | $81.00K | $-276.33M | $544.42M | 3 month · $6.00M | $0.00 | $820.66M | (m) | 9 month · $0.00 |
| 2020-06-30 | $6.00K | $144.00K | $-278.15M | $428.71M | 3 month · $4.47M | $0.00 | $706.71M | 3 month · $21.63M | 6 month · $0.00 |
| 2020-03-31 | $4.00K | $288.00K | $-233.08M | $140.64M | 3 month · $3.46M | $0.00 | $373.43M | (m) | 3 month · $0.00 |
| 2019-12-31 | $4.00K | $64.00K | $-205.33M | $164.00M | 12 month · $8.98M | $0.00 | $369.10M | (m) | 12 month · $0.00 |
| 2019-09-30 | $4.00K | $53.00K | $-188.73M | $177.23M | 3 month · $2.74M | $0.00 | $365.90M | (m) | 9 month · $0.00 |
| 2019-06-30 | $4.00K | $113.00K | $-166.38M | $196.65M | 3 month · $2.13M | $0.00 | $362.90M | (m) | 6 month · $0.00 |
| 2019-03-31 | $4.00K | $29.00K | $-138.29M | $221.57M | 3 month · $1.67M | $0.00 | $359.82M | (m) | 3 month · $0.00 |
| 2018-12-31 | $4.00K | $-107.00K | $-122.83M | $234.94M | 12 month · $3.87M | $0.00 | $357.87M | (m) | 12 month · $0.00 |
| 2018-09-30 | $4.00K | $-108.00K | $-110.53M | $245.12M | 3 month · $1.05M | $0.00 | $355.76M | (m) | 9 month · $0.00 |
| 2018-06-30 | $4.00K | $-83.00K | $-99.72M | $254.57M | 3 month · $1.12M | $0.00 | $354.38M | (m) | 6 month · $0.00 |
| 2018-03-31 | $4.00K | $-97.00K | $-86.19M | $266.59M | 3 month · $656.00K | $0.00 | $352.87M | (m) | 3 month · $0.00 |
| 2017-12-31 | (m) | $-42.00K | $-73.23M | $-72.33M | 12 month · $495.00K | (m) | $948.00K | (m) | 12 month · $0.00 |
| 2016-12-31 | (m) | (m) | (m) | $-19.99M | 12 month · $90.00K | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | $-2.17M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |